

# Mari Ariyasu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4842009/publications.pdf>

Version: 2024-02-01

5  
papers

1,089  
citations

1684188

5  
h-index

2053705

5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

847  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 226-240.	9.1	411
2	Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1319-1328.	9.1	285
3	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 213-225.	9.1	255
4	Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx176.	0.9	113
5	&lt;p&gt;Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens â€“ The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study&lt;/p&gt;. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 3607-3623.	2.7	25